Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
about
Clinical significance of microRNAs in chronic and acute human leukemiaThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyMicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tuneTherapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsMicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid LeukaemiamiR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon responseDisruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation.miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.Nanopharmacology in translational hematology and oncologyMicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells.Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.Acute myeloid leukemia: 2014 update on risk-stratification and management.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaMicroRNAome genome: a treasure for cancer diagnosis and therapy.High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients.Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.The Globalization of Cooperative Groups.MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemiaThe expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemiaUncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach.High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.The Role of miRNA in Haematological Malignancy.A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreTargeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.The pivotal role of microRNA-155 in the control of cancer.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.The use of molecular genetics to refine prognosis in acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?
P2860
Q26749533-BC948045-F790-48D6-AE4B-E8C5ADFF05C9Q26799596-90E0D092-8E51-489F-BCD4-C14E0F02721DQ27013740-5C3F51E5-AF10-4E44-9FE8-7A75A68B36BEQ28071427-B75B56CE-CC62-471E-A8BA-1A9D73E9EB91Q33612847-66A66BAD-95C6-4419-8C3D-D037D3346EF4Q33782332-3D22C63B-BAD4-411B-B218-1C388DCBF439Q33854384-62187E69-F56A-461F-87C4-E792166BC54CQ33872395-F235A620-DEFA-48CE-8665-59F729888955Q33961538-905FB517-F47E-429B-94C0-1386C13E2E92Q34444017-57FDEC01-A037-4C3B-B6A9-046828D2352FQ34476246-A12FEE29-7A2A-4812-B8EB-123A9E18F9BFQ34551206-A235D255-0208-4D36-B55F-A29B127F18D4Q34665691-B70ECCA5-2321-41BC-AD55-52A6749B612EQ34831106-3F76987F-F128-42B9-B1AF-152346D7F2AAQ35152173-A8E17102-FC35-4AE7-8460-3A1F462B4879Q35704188-8AA63530-DB50-4D66-B449-F734BCEB66BDQ35741669-B510A394-F7FB-4873-82B1-0FDC79D52392Q35781530-C574F9E8-BC40-402D-BAD6-186028AB2376Q35814995-44C54EEF-B3F0-4C6F-9AF4-0216B59095F6Q35879526-64393602-9E32-493D-AE86-34D6AECBAAE5Q36069041-F3739276-B46F-40EF-A0F5-DF8BE908B89CQ36119749-A9B44049-8092-44AD-A576-4762D8AB401EQ36140715-C350FF50-EC93-4F9B-BC2C-112C644E5BBDQ36248867-632C7C21-BF5D-455C-B14C-2C3485A2D52AQ36254225-A5B19369-9B06-40E0-8E9B-AFB1E2B993EEQ36256357-DC05C8D8-D457-4776-8B81-5206F7C9F77FQ36544646-067C30D1-649D-4152-8FFA-6EB978889BD3Q36586471-4AEE5DB0-9F0D-4DEE-99B3-4B08B00CCC4CQ36771874-3267CFCA-2885-4E0D-860A-026C315B12D7Q36956053-5E1C09AA-24F6-40B0-9918-D7D37B93D946Q37085891-10A54F73-1B40-44D8-BA25-13A1E6D3CA7EQ37422388-E91D6B01-2832-4218-876D-4F04DF74764BQ37474559-1364F3E8-AA4A-4998-977D-28257EC69B9FQ37510247-A696934A-DA68-47DE-8ECC-1A1E7CA4C9A2Q37570427-694663CD-617D-4633-B32B-9A691C9B1EB7Q37644854-E1C6EAD0-8FC5-4A93-A76E-5B6589538C02Q38152297-DCB68CBA-315E-4F09-AA2F-45447546C7B1Q38183943-EB10F88E-84B0-4AD3-B54D-810AB4451439Q38198569-F7F4ADF5-A500-462A-9E80-83DBBB60E831Q38199056-8915C4F3-C3FB-4BD5-9798-9DEA41D8D7D7
P2860
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical role of microRNAs in ...... identifies high-risk patients
@en
Clinical role of microRNAs in ...... identifies high-risk patients.
@nl
type
label
Clinical role of microRNAs in ...... identifies high-risk patients
@en
Clinical role of microRNAs in ...... identifies high-risk patients.
@nl
prefLabel
Clinical role of microRNAs in ...... identifies high-risk patients
@en
Clinical role of microRNAs in ...... identifies high-risk patients.
@nl
P2093
P2860
P50
P356
P1476
Clinical role of microRNAs in ...... identifies high-risk patients
@en
P2093
Andrew J Carroll
Ann-Kathrin Eisfeld
Bayard L Powell
Deedra Nicolet
Heiko Becker
Jason H Mendler
Jonathan E Kolitz
Kati S Maharry
Michael A Caligiuri
Ramiro Garzon
P2860
P304
P356
10.1200/JCO.2012.45.6228
P407
P50
P577
2013-05-06T00:00:00Z